A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT07174583. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients With DLL3-Expressing Tumors Including Small Cell Lung Cancer
Study identification
- NCT ID
- NCT07174583
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- IDEAYA Biosciences
- Industry
- Enrollment
- 262 participants
Conditions and interventions
Interventions
- IDE849 Drug
- durvalumab Drug
- IDE161 Drug
- Carboplatin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 13, 2025
- Primary completion
- Jun 30, 2029
- Completion
- Jun 30, 2029
- Last update posted
- Jul 8, 2026
2025 – 2029
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sarah Cannon Research Institute at HealthONE | Denver | Colorado | 80218 | Recruiting |
| Sarah Cannon Research Institute at Florida Cancer Specialists | Orlando | Florida | 32827 | Recruiting |
| Fort Wayne Medical Oncology and Hematology, Inc. - Fort Wayne North Office | Fort Wayne | Indiana | 46825-1623 | Recruiting |
| START Midwest | Grand Rapids | Michigan | 49546 | Recruiting |
| The Cancer and Hematology Centers | Grand Rapids | Michigan | 49546 | Recruiting |
| Columbia University Medical Center - Herbert Irving Pavilion | New York | New York | 10032 | Recruiting |
| Sidney Kimmel Cancer Center at Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | Recruiting |
| Sarah Cannon Research Institute - Oncology Partners | Nashville | Tennessee | 37203 | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030-4000 | Recruiting |
| Oncology Consultants, PA- Houston | Houston | Texas | 77030 | Recruiting |
| Next Oncology Dallas | Irving | Texas | 75039 | Recruiting |
| NEXT Oncology Virginia | Fairfax | Virginia | 22031 | Recruiting |
| Swedish Cancer Institute | Seattle | Washington | 98104 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07174583, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 8, 2026 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07174583 live on ClinicalTrials.gov.